Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

(NQ: )

N/A UNCHANGED
Last Price Updated: Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All news about

< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Apricus Reports Top-Line Phase 2a Data for RayVa(TM), Its Topical Treatment for Raynaud's Phenomenon
Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today ... 
Tags Press Releases APRI AKRX
From Benzinga
Apricus Reports Top-Line Phase 2a Data for RayVa(TM), Its Topical Treatment for Raynaud's Phenomenon
Apricus Reaffirms Plans to Move RayVa Into Late-Stage Clinical Trials in Patients With Scleroderma Who Also Suffer From Raynaud's Phenomenon 
From GlobeNewswire News Releases
Morning Market Gainers
Envivio Inc (NASDAQ: ENVI) shares jumped 113.16 percent to $4.05 after the company agreed to be acquired by Ericsson (ADR) (NASDAQ: ... 
Tags Market Gainers ERIC News
From Benzinga
Apricus Biosciences Enters Into License Agreement With Allergan for the U.S. Rights to Vitaros
Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today ... 
Tags News Benzinga Press Releases
From Benzinga
Apricus Biosciences Enters Into License Agreement With Allergan for the U.S. Rights to Vitaros(TM)
Apricus to Lead Clinical and Regulatory Efforts; Allergan Retains Commercialization Option in U.S. 
From GlobeNewswire News Releases
Apricus Biosciences to Present at the Rodman & Renshaw 17th Annual Global Investment Conference
From GlobeNewswire News Releases
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Italy by Bracco SpA
From GlobeNewswire News Releases
Mid-Day Market Update: Thursday's Movers, Feds Meet But No Answers Met
The U.S. stock market tumbled for the third straight day after growth worries manifest investors’ thoughts. The Federal Reserve ... 
Tags ACI News Benzinga
From Benzinga
Apricus Biosciences Announces it is Seeking a Global Partner for Femprox, a Novel Treatment for Female Sexual Dysfunction
From GlobeNewswire News Releases
Apricus Biosciences Announces Approval of Vitaros(R) for the Treatment of Erectile Dysfunction in Twelve Additional Countries
Vitaros Now Approved in Twenty-Two Countries in Europe Under the Decentralized Procedure 
From GlobeNewswire News Releases
Apricus Biosciences Provides Corporate Update and Second Quarter 2015 Financial Results
From GlobeNewswire News Releases
Apricus Biosciences to Present at the Canaccord Genuity 35th Annual Growth Conference
From GlobeNewswire News Releases
Apricus Biosciences Announces Corporate Update and Second Quarter 2015 Financial Results Conference Call
From GlobeNewswire News Releases
Rodman & Renshaw 2015 Annual Global Investment Conference to be held in New York from September 8 to 10, 2015
From PR Newswire
US Stock Futures Signal Lower Start On Wall Street
Pre-open movers US stock futures traded lower in early pre-market trade. The Empire State manufacturing for June will be released ... 
Tags News ONCY SAIC
From Benzinga
Apricus Biosciences Announces Last Patient Enrolled in RayVa Phase 2a Clinical Trial for Raynaud's Phenomenon in Patients With Scleroderma
Apricus Biosciences, Inc. (Nasdaq: APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today ... 
Tags FDA Benzinga News
From Benzinga
Apricus Biosciences Announces Last Patient Enrolled in RayVa(TM) Phase 2a Clinical Trial for Raynaud's Phenomenon in Patients With Scleroderma
From GlobeNewswire News Releases
Apricus Biosciences Enrolls First Patients in Phase 2b Clinical Trial for Fispemifene in Men With Symptomatic Secondary Hypogonadism
Topline Data Expected in the First Quarter of 2016 
From GlobeNewswire News Releases
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in France by Laboratoires Majorelle
To Be Commercialized in France as Vitaros(R) 
From GlobeNewswire News Releases
Apricus Biosciences Provides Corporate Update and First Quarter 2015 Financial Results
Conference Call / Webcast Today, Monday, May 11, 2015 at 8:30 a.m. ET 
From GlobeNewswire News Releases
Apricus Biosciences Announces the Launch of Its Novel Topical Treatment for Erectile Dysfunction in Spain by Recordati
From GlobeNewswire News Releases
Apricus Biosciences Announces Corporate Update and First Quarter 2015 Financial Results Conference Call
Conference Call and Webcast to be Held on Monday, May 11, 2015 at 8:30 a.m. ET 
From GlobeNewswire News Releases
Apricus Biosciences to Present at Two Investor Conferences in May
From GlobeNewswire News Releases
Apricus Biosciences, Inc. to Present at Taglich Brothers 12th Annual Investment Conference
From Marketwired News Releases
Ritter Pharmaceuticals Names Paul V. Maier to its Board of Directors
From Business Wire News Releases
Apricus Biosciences Provides Corporate Update and 2014 Year-End Financial Results
Conference Call / Webcast Today, Monday, March 16, 2015 at 8:30 a.m. ET 
From GlobeNewswire News Releases
Apricus Biosciences Announces Corporate Update and Fourth Quarter and Year-End 2014 Financial Results Conference Call
Conference Call and Webcast to be Held Monday, March 16, 2015 at 8:30 a.m. ET 
From GlobeNewswire News Releases
Apricus Biosciences to Present at the 27th Annual Roth Conference
From GlobeNewswire News Releases
SeeThruEquity Initiates Coverage on Apricus Biosciences, Inc. with Price Target of $4.22
From ACCESSWIRE
10 cheapest stocks in the Nasdaq’s hottest sector
A handful of health-care stocks have doubled this year, and one has quadrupled, writes Phil van Doorn. 
Tags Health/Care Medical Products General
From MarketWatch
< Previous 1 2 3 4 5 6 7 8 9
...
14 15 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.